Table 1.
Study population characteristics and circulating biomarker levels according to arrays used for genotyping.
| GWAS Array |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Affymetrix Axiom (N=366) |
Illumina 1M/1M Duo (N=794) |
Illumina Omni1 (N=411) |
Illumina OncoArray (N=217) |
||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD |
P
for differences |
|
| Age, yrs | 52.3 | 11.5 | 59.1 | 11.0 | 55.1 | 10.9 | 50.0 | 10.6 | <0.001 |
| BMI, kg/m2 | 26.8 | 5.3 | 26.6 | 5.0 | 26.8 | 4.9 | 27.2 | 5.4 | 0.50 |
| N | % | N | % | N | % | N | % | ||
| Female | 200 | 54.6 | 410 | 51.6 | 228 | 55.5 | 101 | 46.5 | 0.14 |
| Current alcohol intake status, yes | 223 | 60.9 | 517 | 65.1 | 207 | 50.4 | 104 | 47.9 | <0.001 |
| Current smoking status, yes | 49 | 13.4 | 84 | 10.6 | 58 | 14.1 | 20 | 9.2 | 0.13 |
| A history of adenomas | 83 | 22.7 | 91 | 11.5 | 115 | 28.0 | 15 | 6.9 | <0.001 |
| Center | <0.001 | ||||||||
| Ontario | 90 | 24.6 | 384 | 48.4 | 104 | 25.3 | 0 | ||
| USC/CSMC consortium | 79 | 21.6 | 0 | 0 | 114 | 27.7 | 0 | ||
| Australia | 93 | 25.4 | 173 | 21.8 | 10 | 2.4 | 0 | ||
| Mayo | 37 | 10.1 | 0 | 0 | 98 | 23.8 | 0 | ||
| Seattle | 67 | 18.3 | 237 | 29.8 | 85 | 20.7 | 217 | 100 | |
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | ||
| Creatinine, mg/dl | 2.4 | 1.3 | 2.3 | 1.0 | 2.3 | 1.3 | 2.0 | 0.8 | <0.001 |
| SAH, ng/ml | 9.4 | 12.7 | 11.2 | 15.9 | 11.4 | 12.9 | 5.1 | 7.3 | <0.001 |
| tHCY, umol/l | 13.2 | 11.2 | 11.5 | 8.2 | 11.6 | 8.8 | 8.7 | 8.5 | <0.001 |
| METH, umol/l | 15.4 | 16.5 | 31.4 | 24.7 | 14.9 | 16.9 | 22.8 | 20.6 | <0.001 |
| CYSTA, ng/ml | 35.8 | 60.4 | 47.0 | 66.3 | 51.2 | 65.8 | 86.0 | 96.9 | <0.001 |
| SAM, ng/ml | 90.5 | 219.4 | 142.5 | 208.3 | 56.7 | 170.8 | 98.8 | 195.5 | <0.001 |
| Riboflavin, nmol/l | 1.1 | 11.7 | 0.6 | 18.0 | 1.9 | 16.2 | 15.3 | 43.3 | <0.001 |
| FMN, ng/ml | 2.7 | 12.0 | 11.4 | 30.0 | 3.0 | 15.7 | 6.2 | 11.5 | <0.001 |
| Pyridoxic acid, ng/ml | 2.5 | 13.9 | 2.1 | 24.4 | 7.2 | 23.1 | 7.3 | 23.2 | 0.0003 |
| Pyridoxal, ng/ml | 2.5 | 38.0 | 4.1 | 50.7 | 0.6 | 5.5 | 2.9 | 10.3 | <0.001 |
| Pyridoxamine, ng/ml | 1.9 | 2.1 | 2.1 | 1.9 | 2.1 | 2.5 | 1.5 | 2.0 | 0.001 |
| 5-MTHF, ng/ml | 6.3 | 16.2 | 9.0 | 19.0 | 10.0 | 17.1 | 21.3 | 24.4 | <0.001 |
| Ratio of SAM to SAH | 5.2 | 20.4 | 12.7 | 33.8 | 2.5 | 12.4 | 13.9 | 30.8 | <0.001 |
| Ratio of SAH to HCY | 0.005 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.005 | 0.01 | <0.001 |
| Ratio of tHCY to METH | 0.7 | 1.2 | 0.3 | 0.5 | 0.6 | 0.8 | 0.3 | 0.3 | <0.001 |
| Ratio of tHCY to CYSTA | 54.8 | 139.9 | 30.8 | 68.3 | 35.9 | 90.5 | 15.0 | 28.9 | <0.001 |
Abbreviation: SD, standard deviation. IQR, interquartile range. SAH, S-adenosylhomocysteine. SAM, S-adenosylmethionine. tHCY, total Homocysteine.
CYSTA, Cystathionine. FMN, Flavin-mononucleotide. 5-MTHF, 5-methyltetrahydrofolate.